stockportfolio.pro
LeMaitre Vascular, Inc. (LMAT)
Healthcare · Medical Instruments & Supplies · NasdaqGM
LeMaitre Vascular, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $89.15M | $100.87M | $105.57M | $117.23M | $129.37M | $154.42M | $161.65M | $193.48M | $219.86M | $249.60M |
| Gross profit | $62.94M | $70.70M | $73.94M | $79.85M | $84.62M | $101.38M | $104.90M | $127.05M | $150.90M | $178.54M |
| Net income | $10.59M | $17.18M | $22.94M | $17.93M | $21.22M | $26.91M | $20.64M | $30.11M | $44.04M | $57.73M |
| Net margin | 11.9% | 17.0% | 21.7% | 15.3% | 16.4% | 17.4% | 12.8% | 15.6% | 20.0% | 23.1% |
Source: LeMaitre Vascular, Inc. SEC filings (10-K). 17 years of history available in the interactive view.
Explore 17 years of LeMaitre Vascular, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track LMAT in your portfolio →
About LeMaitre Vascular, Inc.
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
LeMaitre Vascular, Inc. — frequently asked questions
What is LeMaitre Vascular, Inc.'s revenue?
LeMaitre Vascular, Inc. (LMAT) reported revenue of $249.60M for fiscal year 2025, up 13.5% from the prior year, according to its SEC filings.
Is LeMaitre Vascular, Inc. profitable?
Yes. LMAT earned net income of $57.73M in fiscal 2025, a net margin of 23.1%.
What is LMAT's P/E ratio?
LeMaitre Vascular, Inc. trades at a price-to-earnings ratio of about 34.1 based on the latest data in our nightly-refreshed cache.
How fast is LeMaitre Vascular, Inc. growing?
LMAT's revenue grew at roughly 14.0% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from LeMaitre Vascular, Inc.'s official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.